PROSILICO (http://prosilico.com/) is a leader in ADME/PK-predictions. 

With new, unique ADME/PK-prediction methods and services, and an integrated ADME/PK-platform, PROSILICO predicts human and animal in-vivo ADME/PK, doses and exposures direct from molecular structure and clearly outperforms state-of-the-art in-vitro and animal in-vivo based methods.

Models (n=134; including many exclusive) have a higher sensitivity and broader ranges than commonly used models and demonstrate an overall <2-fold median prediction error. Prediction models for fraction absorbed and hepatic clearance beat Caco-2, microsome and hepatocyte models.

Models are applicable for drug candidates, competitor drugs, metabolites (including actual and relative exposures), food constituents and chemicals.

PROSILICO also evaluates customers’ data (Gapfinder) and fills gaps with reliable predictions (Gapfiller).
Preliminary results are normally reported within 2 working days.

Benefits for customers include improved quality and knowledge, reduced uncertainty and risks, increased data production, reduced animal experiments and substance synthesis, frontloaded and improved decision-making, ethical, safety and environmental advantages, committed expert support, and savings of costs and time.

This Swedish company was founded in July 2014 by ex-AstraZeneca pharmacokineticist, PhD and associate professor in biopharmaceutics/pharmacokinetics Urban Fagerholm.

NOW FREE EVALUATION of in-vitro and animal ADME/PK-data (max 2 compounds) for non-customers/new customers. Finds the gaps. Fills the gaps (half price for new customers)

PROSILICO

Org chart

Teams

Offices